Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group
- 30 November 2006
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (17), 2991-2995
- https://doi.org/10.1016/j.ejca.2006.08.012
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanomaAnnals of Oncology, 2006
- Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma GroupJournal of Clinical Oncology, 2005
- Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatinEuropean Journal Of Cancer, 2002
- Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical TrialJournal of Clinical Oncology, 2002
- Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)British Journal of Cancer, 2002
- Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)British Journal of Cancer, 2001
- Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trialsMelanoma Research, 2001
- Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.Journal of Clinical Oncology, 1998